Monoclonal antibodies specific to FAS ligands and their use

Monoclonal antibodies targeting FasL are developed to inhibit its function, offering therapeutic benefits for multiple diseases by blocking FasL signaling with higher affinity, addressing the lack of effective FasL-targeted agents.

JP2026510185APending Publication Date: 2026-04-02PROVIDENCE HEALTH & SEVICES OREGON
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-10-30
Publication Date
2026-04-02

AI Technical Summary

Technical Problem

There are currently no clinically approved FasL-targeted therapeutic agents available to address the role of FasL in various human diseases and disorders, including cancer, myocardial infarction, stroke, hepatic ischemia-reperfusion injury, renal ischemia-reperfusion injury, sepsis, interstitial lung disease, and autoimmune diseases.

Method used

Development of monoclonal antibodies that specifically bind to Fas ligand (FasL) with high affinity and block its function, along with conjugates, fusion proteins, bispecific antibodies, chimeric antigen receptors (CARs), and immunoconjugates to inhibit FasL signaling.

Benefits of technology

The antibodies effectively inhibit FasL signaling, providing therapeutic options for treating conditions such as cancer, sepsis, myocardial infarction, stroke, hepatic and renal ischemia-reperfusion injury, interstitial lung disease, and autoimmune diseases with enhanced potency compared to previous drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2026510185000001_ABST
    Figure 2026510185000001_ABST
Patent Text Reader

Abstract

This disclosure describes a monoclonal antibody that specifically binds to Fas ligand (FasL) and blocks its function. FasL-specific antibodies can be used in the development of therapeutic agents for the treatment of diseases, disorders, and conditions associated with the Fas / FasL signaling pathway, such as cancer, sepsis, ischemia-reperfusion injury, and coronavirus disease 2019 (COVID-19). This disclosure describes a monoclonal antibody that specifically binds to Fas ligand (FasL) and blocks its function. Furthermore, this specification describes the use of the disclosed antibody in the development of therapeutic agents for the treatment of diseases and conditions associated with the Fas / FasL signaling pathway.
Need to check novelty before this filing date? Find Prior Art